Hypoglycaemia

[1]

Meet the patient

A 72-year-old man with type 2 diabetes on glibenclamide is found unconscious at home by his wife. He is clammy, breathing, and his capillary glucose reads 1.8 mmol/L. The stroke team is already at the bedside.[25]

The first question is the one that decides the next hour: what do you give — and why will one bolus not be enough? Sulfonylurea-driven insulin release keeps recurring — in reported adult series hypoglycaemia recurred in 22-50 per cent of patients treated for sulfonylurea poisoning — so the rebound is the trap that sends him back unconscious at 4 am. Hold that, and the whole of hypoglycaemia falls into place.[12]

Whipple's triad — the gate to every investigation

Hypoglycaemia is, formally, a plasma glucose low enough to produce symptoms or to warrant intervention. The brain is almost totally dependent on a continuous supply of glucose, and deprivation of it rapidly causes cerebral malfunction.[11]

The threshold for clinical hypoglycaemia is debated, but the physiological defences give three concentric landmarks:[1][2]

• Counterregulatory activation — in clamp studies glucagon, adrenaline, noradrenaline and growth hormone secretion all begin at plasma glucose about 3.6 to 3.8 mmol/L (65 to 68 mg/dL).[21]
• Autonomic warning symptoms — sweating, tremor, palpitations, anxiety and irritability begin at about 3.2 mmol/L (58 mg/dL), and cognitive function is measurably impaired once glucose falls below 3 mmol/L.[21][11]
• Severe hypoglycaemia (operational definition) — an event requiring assistance of another person; this is the definition used in the landmark trials, where "hypoglycaemia requiring assistance" was more frequent under intensive glucose lowering.[29][6]

The single overarching diagnostic principle is Whipple's triad, without which the diagnosis of true hypoglycaemia (and the justification for invasive investigation) cannot be made:[1]

The clinical skill in hypoglycaemia is not the bedside correction (that is a formula: glucose → recover → reassess) but rather (1) recognising it in the patient who presents with collapse, seizure, confusion, or odd behaviour; (2) treating before diagnostic confirmation when glucose cannot be measured; and (3) in non-diabetic or recurrent presentations, pursuing the cause aggressively with the correct samples drawn during the episode.[1]

Diabetic first, non-diabetic second

Hypoglycaemia is classified in three complementary ways — by clinical severity, by glycaemic threshold, and by causative mechanism. The clinically most useful division is diabetic vs non-diabetic, because it dictates the diagnostic workup.[1][2]

By physiological threshold and clinical severity (ADA / Endocrine Society, in diabetes)[2]

[21] [11] [29] [19]

By glycaemic threshold — the counterregulatory cascade

In a non-diabetic these thresholds are remarkably reproducible; in long-standing insulin-treated diabetes they are shifted to lower glucose values because of hypoglycaemia-associated autonomic failure (HAAF) (see Pathophysiology).[10]

By cause — the framework that drives the differential diagnosis

How common, and who keeps going low

Hypoglycaemia is the commonest acute complication of diabetes treatment and is the principal barrier to achieving good glycaemic control.[5][10]

In type 1 diabetes hypoglycaemia causes recurrent morbidity and is sometimes fatal; the dead-in-bed syndrome — patients found dead in the early morning in an undisturbed bed, typically with a preceding history of recurrent severe hypoglycaemia — has been estimated at 4.7 to 27.3 per cent of all unexplained deaths in T1DM.[10][30]

In type 2 diabetes the population-attributable burden is even greater because of its far higher prevalence; severe hypoglycaemia rates rise sharply with insulin use, sulfonylurea use, and longer duration of disease.[5]

[21] [30] [19] [20] [12]

Risk factors for hypoglycaemia in diabetes (a list an examiner expects verbatim):[2][5]

• Strict glycaemic control (HbA1c low or normal) — the ACCORD, ADVANCE and VADT trials all showed that intensive glucose lowering increases severe hypoglycaemia, and ACCORD was stopped early because of excess mortality in the intensive arm.[7][6]
• Prior severe hypoglycaemia — the strongest single predictor; one severe event multiplies the risk of the next.
• Hypoglycaemia unawareness — defective autonomic warning from an attenuated sympathoadrenal response, the clinical component of HAAF.[10]
• Long duration of insulin-treated diabetes (loss of glucagon response, autonomic neuropathy).
• Renal impairment — reduced insulin clearance and gluconeogenesis; common in elderly T2DM.
• Hepatic failure, heart failure, sepsis, malignancy — impaired gluconeogenesis and glycogen stores.
• Skipping meals, alcohol, exercise without carbohydrate adjustment.
• Drugs: sulfonylureas (especially glibenclamide due to long half-life), insulin, glinides, beta-blockers (mask warning, inhibit gluconeogenesis), ACE inhibitors, pentamidine (initial insulin release), quinine, salicylates.
• Extremes of age — neonates and the elderly have less effective counterregulation.
• Cognitive impairment, dementia — patient cannot recognise or self-treat.[2]

Risk factors for hypoglycaemia in non-diabetics are essentially the causes above; insulinoma occurs in about 1 to 4 per million of the general population, mostly around the fifth decade.[15][16]

The counterregulatory cascade — and why it fails

Understanding hypoglycaemia means understanding glucose homeostasis and its counterregulation. In the fed state, glucose is supplied from food; with fasting, hepatic glycogenolysis and then gluconeogenesis maintain the plasma glucose. The human brain is almost totally dependent on a continuous supply of glucose, deprivation of which rapidly causes malfunction — so a falling glucose triggers a hierarchy of defences, from counterregulatory hormone secretion to warning symptoms, before cerebral function itself fails.[11][21]

The counterregulatory cascade (normal)

When glucose falls, a tightly choreographed physiological response is triggered. The defences that protect glucose stand in a fixed hierarchy:[10][5]

1. Suppression of endogenous insulin — the earliest physiological defence: as glucose falls within the normal range, insulin secretion declines, releasing the liver to produce glucose. In insulin-deficient diabetes this first defence is lost.[10]
2. Glucagon release from pancreatic alpha-cells — the second defence, lost early in type 1 and late in type 2 diabetes; secretion begins at about 3.8 mmol/L (68 mg/dL) in clamp studies.[21][5]
3. Adrenaline release from the adrenal medulla — activated at the same glycaemic threshold (about 68 mg/dL); the patient in insulin-deficient diabetes becomes critically dependent on it. It produces the autonomic warning symptoms, which begin a little lower, at about 3.2 mmol/L (58 mg/dL).[21][5]
4. Growth hormone — secretion also activates at about 3.7 mmol/L (67 mg/dL); cortisol and growth hormone act more slowly to support gluconeogenesis. When the first defences fail, the neurogenic symptoms that prompt the behavioural defence (carbohydrate ingestion) are what keep the patient safe.[21][5]

Why the brain fails

The brain is defenceless against a falling glucose because it is almost totally dependent on a continuous glucose supply and cannot store it; regional vulnerability differs, with the cerebral cortex the most sensitive region. As glucose falls below 3.0 mmol/L, cognitive function deteriorates measurably (complex, attention-demanding and speed-dependent tasks first), EEG changes appear, and neuroglycopenic symptoms (blurred vision, difficulty thinking, dizziness) begin. Deep or prolonged hypoglycaemia progresses to seizures and coma, and cognition may not recover fully until 40 to 90 minutes after glucose is restored.[11][21]

Hypoglycaemia-associated autonomic failure (HAAF) — the key chronic complication

In patients with long-standing insulin-treated diabetes, recurrent hypoglycaemia induces a maladaptive reset of the counterregulatory threshold: both the autonomic response and the glucagon response shift to lower glucose values, and may be abolished altogether. This is termed hypoglycaemia-associated autonomic failure (HAAF) or, clinically, hypoglycaemia unawareness.[10][5]

The mechanism is a central nervous system adaptation — antecedent hypoglycaemia reduces the sympathoadrenal response to subsequent hypoglycaemia (the brain learns to tolerate lower glucose). The clinical consequence is dangerous: the first warning the patient has is neuroglycopenia (confusion, coma) rather than the protective sweating/tremor, so episodes are missed until severe. [10][5]

HAAF is partly reversible with a 2- to 3-week period of scrupulous hypoglycaemia avoidance, which restores hypoglycaemia awareness in most affected patients — the rationale for temporarily relaxing glucose targets and for structured glucose monitoring after any severe event.[10]

The vicious cycle

The pathophysiology of hypoglycaemia in diabetes is a vicious cycle: antecedent hypoglycaemia shifts the glycaemic thresholds for the sympathoadrenal and neurogenic responses to lower plasma glucose, producing unawareness and yet further recurrent hypoglycaemia. Breaking the cycle — addressing the issue, applying the principles of intensive glycaemic therapy with flexible and individualised regimens, and considering both the conventional risk factors and those indicative of compromised counterregulation — is the cornerstone of long-term management.[10][5]

Two waves — autonomic first, neuroglycopenia second

The clinical face of hypoglycaemia is the biphasic symptom complex — autonomic followed by neuroglycopenic. The tempo depends on the cause: sulfonylurea poisoning is typically delayed and persistent (time to hypoglycaemia 1-13 hours after ingestion in reported adult series), whereas insulin-induced hypoglycaemia develops as the insulin acts. [12]

Autonomic (sympatho-adrenal) symptoms — the warning system

Sweating, tremor, palpitations, anxiety and irritability — the neurogenic (autonomic) warning cluster; hunger, dizziness, tingling, blurred vision and difficulty thinking follow as the neuroglycopenic cluster. In clamp studies autonomic symptoms began at a plasma glucose of about 3.2 mmol/L (58 mg/dL) — below the counterregulatory hormone threshold and significantly above the cognitive-deterioration threshold, an ordering that maximises the chance to treat before thinking fails. They are sympathoadrenally mediated, and the whole symptom response shifts to lower glucose after antecedent hypoglycaemia.[21][10]

A time-honoured mnemonic: [1]

Neuroglycopenic symptoms — the danger zone

Difficulty thinking and concentrating, blurred vision, dizziness, confusion, behavioural and personality change, visual disturbance, seizure and coma — the neuroglycopenic cluster. In clamp studies these symptoms (and measurable cognitive deterioration) began at about 2.8 to 2.9 mmol/L (49 to 51 mg/dL), significantly below the autonomic threshold, and cognitive function is measurably impaired below 3 mmol/L. They reflect direct neuronal fuel failure.[21][11][15]

A second mnemonic for neuroglycopenia: [1]

Bedside clinical features at presentation

• Tachycardia, wide pulse pressure, pallor, sweating (sympathetic).
• Confusion, drowsiness, dysarthria, ataxia, seizures, coma (neuroglycopenic).
• Rarely, focal neurological signs (hemiplegic hypoglycaemia — a stroke mimic).
• In children: ** behavioural change, somnolence, seizures, early-morning convulsions**. [1]

Atypical and missed presentations (the exam corners)

• Hypoglycaemia unawareness — in long-standing type 1 diabetes reduced sympathoadrenal responses blunt the warning, so the patient can present with neuroglycopenia without autonomic symptoms; the extreme is the dead-in-bed syndrome — the patient is typically found dead in the early morning, lying in an undisturbed bed, having been well the previous evening, usually with a preceding history of recurrent severe hypoglycaemia and presumed arrhythmia (hypoglycaemia causes an acquired long QT syndrome).[10][30][26]
• Nocturnal hypoglycaemia — sleep is one of the recognized causes of an attenuated sympathoadrenal response (alongside recent antecedent hypoglycaemia and prior exercise), so nocturnal episodes lose their warning and feed the HAAF cycle.[5]
• The elderly diabetic — confusion, falls, focal signs, or functional decline mistaken for stroke or delirium; always check glucose in any altered elderly patient, especially on insulin or sulfonylurea.
• The alcoholic — stupor attributed to intoxication; the actual cause may be alcohol-induced hypoglycaemia, which can be fatal if untreated.
• The pregnant diabetic — tighter glucose targets increase risk; symptoms may be atypical; ketoacidosis can coexist with apparent normoglycaemia.
• Malignancy-driven (NICTH) — recurring fasting hypoglycaemia with a large tumour mass; fibrous tumours are the commonest cause (53 per cent in a systematic review of 233 patients), followed by tumours of the liver, haemangiopericytomas and mesotheliomas.[9]
• Autoimmune insulin syndrome (Hirata) — recurring postprandial hypoglycaemia with high total insulin and detectable insulin autoantibodies; classically in patients with autoimmune disease (Graves, SLE) or after exposure to sulfhydryl drugs (methimazole, captopril).
• Factitious / surreptitious — non-diabetic patients (often healthcare workers) who self-inject insulin or take sulfonylureas; the workup is identical to insulinoma but C-peptide distinguishes exogenous insulin (low) from endogenous (high).

The bedside test that ends the differential

The differential of a patient presenting with altered consciousness, collapse, or seizure is wide; hypoglycaemia is excluded at the bedside by a finger-prick glucose and that test must never be omitted.[1]

[1] [28]

The can't-miss mimics in the unconscious patient — measure glucose in every patient with collapse, seizure, confusion, or reduced GCS:[1]

• Hypoglycaemia (the reversible mimic — excluded at the bedside by a finger-prick glucose).
• Opioid toxicity (pinpoint pupils — give naloxone).
• Meningitis/encephalitis (fever, neck stiffness — LP after CT).
• Intracranial haemorrhage (focal signs, hypertension).
• Sepsis. [1]

The bedside round — glucose before the neurologist

The focused assessment of suspected hypoglycaemia is rapid and combines bedside measurement with history and examination of the cause. [1]

The bedside bundle

1. Capillary (finger-prick) glucose — confirm a low value with two readings if the first is surprising (strip error, contamination). Treat before confirmation if glucose cannot be measured and the patient is symptomatic.[1]
2. ABCDE — Airway (recovery position if unconscious); Breathing (rate, oxygenation); Circulation (pulse, BP, perfusion); Disability (GCS, pupils, blood glucose — this is the step where glucose is checked); Exposure (look for MedicAlert, insulin pump, sulfonylurea packet, injection sites).[1]

Focused history

• Diabetes? Insulin, sulfonylurea, glinide? When was the last dose? Skipped meal? Recent exercise? Alcohol?
• Renal, hepatic, cardiac, or adrenal disease?
• Time of onset, progression, autonomic vs neuroglycopenic phase.
• Previous severe events, hypoglycaemia unawareness, driving.
• Recent bariatric surgery, malignancy, autoimmune disease, drugs (sulfhydryl compounds — methimazole, captopril).
• Occupation (driving, machinery, healthcare worker → factitious). [1]

Focused examination

• Vitals (tachycardia, BP, resp rate, temperature — sepsis?).
• Skin — sweating, pallor (autonomic); hyperpigmentation, palmar crease darkening (Addison's); lipohypertrophy at injection sites (over-injected insulin).
• Hydration, perfusion, capillary refill.
• Neurological — GCS, pupils, focal deficit, seizure activity.
• Abdomen — hepatomegaly (glycogen storage, hepatic failure, malignancy), palpable mass (NICTH).
• Looking for insulin pump (failure, kink, occlusion), injection sites (lipohypertrophy), MedicAlert bracelet. [1]

Bedside manoeuvres and named signs

• Whipple's triad — the diagnostic standard (above).
• Hypoglycaemia unawareness — ask the patient: 'When your glucose is low, do you usually notice?' — a 'no' or 'sometimes' indicates impaired awareness (Clarke or Gold questionnaires quantify it).
• Glucose-reversal test — resolution of symptoms and signs after the plasma glucose is raised is the third arm of Whipple's triad; if it does not occur, search for an alternative or coexisting cause. [1]

Draw the critical sample during the episode

The investigation strategy depends on whether the patient is a known diabetic (manage, then audit the regimen) or non-diabetic / recurrent (pursue the cause aggressively).[1]

Immediate (any patient)

• Capillary glucose (and a laboratory plasma glucose if there is any doubt — capillary readings are unreliable in shock, anaemia, and very high or very low glucose).
• Venous blood gas — glucose, lactate, ketones (β-hydroxybutyrate).
• ECG — exclude arrhythmia, silent MI; hypoglycaemia causes an acquired long QT syndrome through sympathoadrenal stimulation.[26]
• U&E, FBC, LFT, CRP, blood cultures if sepsis suspected.
• Chest X-ray, urine dipstick looking for sepsis source.

In the diabetic (cause of the episode — audit)

• Review the regimen (insulin type, dose, timing; sulfonylurea, glinide).
• Review meal / exercise / alcohol around the event.
• HbA1c — overly tight control? a low HbA1c in a hypoglycaemia-prone patient is a red flag.
• Renal function — declining eGFR reduces clearance of insulin and sulfonylureas (especially glibenclamide — contraindicated if eGFR under 30).
• Consider CGM (or flash glucose monitoring) for 1-2 weeks to detect asymptomatic and nocturnal hypoglycaemia. [1]

In the NON-diabetic or recurrent patient — the diagnostic 'trough' samples

The single most important principle is that the diagnostic samples must be drawn DURING the spontaneous symptomatic episode, before any glucose is given. Once glucose is administered, insulin, C-peptide, proinsulin and β-hydroxybutyrate are no longer interpretable.[1]

The critical (trough) sample — during documented symptomatic hypoglycaemia with Whipple's triad:[1]

• Plasma glucose (laboratory).
• Insulin (raised in insulinoma, sulfonylurea, autoimmune; low in NICTH, adrenal insufficiency, critical illness).
• C-peptide (raised if endogenous insulin is the cause; low if exogenous insulin).
• Proinsulin (raised in insulinoma — unlike in surreptitious insulin).
• β-hydroxybutyrate — suppressed when endogenous insulin is high (insulin suppresses lipolysis and ketogenesis); a core element of the Endocrine Society critical sample.
• Sulfonylurea and meglitinide screen — positive in sulfonylurea-induced (factitious, accidental).
• Cortisol, growth hormone — exclude adrenal insufficiency, hypopituitarism.
• IGF-I, IGF-II — include in the panel when a non-islet cell tumour is among the clinical clues.
• Insulin antibodies — autoimmune insulin syndrome.
• Blood alcohol, lactate, ammonia — exclude alcohol, inborn errors.
• Blood cultures, septic screen if sepsis. [1]

The prolonged supervised fast — insulinoma diagnosis

When spontaneous hypoglycaemia cannot be captured, perform a prolonged supervised fast in hospital — the standard endocrine test on which insulinoma diagnosis rests:[1][15]

• Stop caloric intake; allow non-caloric clear fluids.
• Monitor capillary glucose closely throughout, and more often once symptoms begin.
• Draw the critical sample at the moment symptomatic hypoglycaemia with Whipple's triad occurs — or when the fast reaches its protocol end-point if it never does — and then terminate with glucose.
• Diagnosis of suspected cases is based on standard endocrine tests performed during the fast, especially this prolonged fasting test.[15]

A mixed-meal test is used when the hypoglycaemia is postprandial (post-gastric-bypass): a high-glucose meal with paired glucose and insulin measurements; symptomatic postprandial hypoglycaemia with inappropriately high insulin supports late dumping / nesidioblastosis.[1]

Localising an insulinoma

Once biochemical diagnosis is made, localise:[16]

• Multiphase CT pancreas (or MRI) — the routine first-choice preoperative localisation test.[16]
• Endoscopic ultrasound (EUS) — highly accurate in preoperative localisation and frequently superior to non-invasive techniques; allows fine-needle aspiration.[15]
• Molecular imaging (somatostatin-receptor and GLP-1-receptor PET) — an area of rapid advance, increasingly used for occult lesions.[23]
• Selective arterial stimulation with hepatic venous sampling (ASVS) — invasive, highly accurate, used when standard imaging is negative or multifocal disease is suspected. [15]

The 15-15 rule, and what glucagon cannot do

[19] [12] [28] [27] [17] [9]

Hypoglycaemia is a time-critical emergency. The principle is treat first, investigate after — never delay glucose while awaiting laboratory confirmation. The bedside rule of thumb: any unconscious or seizing patient gets a finger-prick glucose immediately, and a low value is treated as hypoglycaemia until disproven.[1][2]

The immediate bundle (ABCDE)

1. Airway — recovery position if reduced GCS; airway adjunct if needed.
2. Oxygen if hypoxic.
3. Capillary glucose in every patient with collapse, seizure, confusion, or reduced GCS.
4. IV access.
5. Treat the glucose. [1]

Mild / moderate (patient conscious, able to swallow) — the 15-15 rule

The 15-15 rule is the patient-facing rule taught to every diabetic:[2]

• Give 15-20 g of oral glucose or sucrose (glucose tablets, or a sugary drink) — the guideline-endorsed dose for the responsive adult.[19]
• Recheck capillary glucose after 10-15 minutes and repeat the dose if the patient is still hypoglycaemic.[19]
• Once glucose recovers, further carbohydrate intake is needed to prevent relapse — recurrence occurred in 22-50 per cent of adults treated for sulfonylurea poisoning in reported series, so keep carbohydrate coming after a sulfonylurea-induced event.[12]

Severe (patient unconscious, fitting, or unable to swallow safely)

Two equally acceptable first-line agents; choice depends on IV access, the cause, and availability.[1][2]

IV dextrose — preferred where IV access is available: [1]

• Adults: IV 10% dextrose, titrated to clinical response — the guideline-endorsed agent for the unresponsive adult.[19]
• Children: a weight-based 10% dextrose bolus per local paediatric protocol, then an infusion if needed.
• Effect: glucose rises within minutes; the patient usually wakes shortly after.
• Caution: in chronic alcohol misuse with a suspected poor diet, give parenteral B vitamins (thiamine) at the outset — before or alongside dextrose — to prevent Wernicke encephalopathy.[27]
• After the bolus, continue a dextrose infusion until the patient can eat and the underlying cause is addressed; for insulin overdose the mainstay is an IV dextrose infusion maintaining blood glucose roughly between 5.5 and 11 mmol/L, with frequent rechecking.[13]

IM / SC glucagon — when IV access is impossible or being sought: [1]

• Adults: 1 mg IM — the standard rescue dose for severe hypoglycaemia in the unresponsive adult.[19][20]
• A needle-free intranasal preparation (3 mg) is non-inferior to 1 mg IM glucagon for insulin-induced hypoglycaemia and far easier for an untrained rescuer.[20]
• In trial conditions mean time to treatment success was about 10-15 minutes (13 min IM, 16 min intranasal); if there is no response, give IV dextrose.[20]
• After recovery, give oral long-acting carbohydrate to replete glycogen.
• Sulfonylurea / meglitinide overdose — the problem is driven insulin release, and dextrose itself stimulates further insulin secretion; octreotide is the specific insulin-suppressing therapy (below).[14][12]
• Glucagon causes nausea and vomiting (roughly a third of dosing visits in trials) — beware airway in the obtunded patient. [20]

Buccal glucose gel (e.g. GlucoGel, 40% dextrose gel squeezed into the buccal mucosa) is useful as first aid in a conscious but uncooperative patient or in neonates; ineffective if mucosal perfusion is poor. [1]

Treat the glucose, then find and fix the cause

Once the patient is resuscitated, the definitive management is cause-directed. The stepwise approach below addresses the common scenarios in turn. [1]

Step 1 — Stop ongoing offending agents

• Insulin overdose (self or iatrogenic) — adjust the dose; review injection technique and meal timing; check renal function. Once hypoglycaemia has been corrected with an IV dextrose bolus, the mainstay is an IV dextrose infusion maintaining blood glucose between about 5.5 and 11 mmol/L for as long as the insulin preparation keeps acting, with frequent glucose assessment; enteral feeding helps if the patient is alert and able to eat.[13]
• Sulfonylurea overdose — hypoglycaemia may be delayed and persistent: in reported adult series, time to hypoglycaemia after ingestion was 1-13 h, and 22-50 per cent recurs even on treatment.[12] Management:
  • Refer for medical assessment; all intentional overdoses are admitted.[13]
  • Correct initial hypoglycaemia with an IV dextrose bolus, then give octreotide 50 mcg SC or IV, followed by three further 50 mcg doses every 6 h — it prevents insulin secretion and maintains euglycaemia, and is superior to dextrose alone (or diazoxide) at preventing rebound.[12][14]
  • Spare IV dextrose where possible — escalating dextrose drives escalating insulin release.[22]
  • Prophylactic IV dextrose is not recommended; enteral feeding is encouraged in alert patients.[13]
  • Observe for 12 h after IV dextrose (and octreotide, if given) is discontinued.[13]
• Glinide overdose — managed like sulfonylurea overdose; observation periods vary with drug, formulation, and dose.[13]

Step 2 — Address the underlying cause

[16] [17] [18] [12] [13] [28] [27] [9] [24] [1]

Step 3 — Prevent recurrence (the long view)

For the diabetic patient, recurrence prevention is the highest-yield intervention:[2][10]

• A 2- to 3-week period of scrupulous hypoglycaemia avoidance after any severe episode — this reverses hypoglycaemia unawareness in most affected patients and is the rationale for temporarily relaxing glucose targets.[10]
• Review the regimen: flexible and individualised drug regimens — review dose, timing and type of glucose-lowering drugs, patterns of food ingestion and exercise, interactions with alcohol and other drugs, and altered sensitivity to or clearance of insulin.[10]
• Education: the 15-15 rule, meal planning, exercise and alcohol advice; patients should be given tools to report hypoglycaemia at each visit.[2][19]
• Continuous glucose monitoring (CGM) — a recognised component of management in hypoglycaemia-prone disease, alongside education and individualised regimens.[17]
• Glucagon rescue kit prescribed to patients at risk and their carers — a needle-free intranasal glucagon preparation performed as well as reconstituted injectable glucagon in a randomised crossover trial and avoids the reconstitution step prone to error or omission.[20]
• Driving: in the UK, DVLA rules restrict driving after severe hypoglycaemia and impaired awareness of hypoglycaemia is notifiable — check current DVLA guidance.
• Screen for HAAF (history of severe hypoglycaemia, hypoglycaemia unawareness, or both) and structure follow-up around hypoglycaemia risk-factor reduction.[1]

The subtypes that bite

A handful of presentations are examined so predictably that they deserve their own treatment. [1]

Insulinoma — the exam-favourite non-diabetic cause

A rare tumour — 1 to 4 per million of the general population, peaking around the fifth decade — of pancreatic beta-cells; in a systematic review of 6222 cases they were mostly sporadic (94 per cent), benign (87 per cent), single (90 per cent), and smaller than 20 mm (84 per cent), distributed almost equally through the pancreas.[15][16] The classic history is Whipple's triad with fasting neuroglycopenic symptoms that the patient learns to avert by frequent eating — leading to weight gain.[15]

• Diagnosis: biochemical first — endocrine testing during the prolonged supervised fast (insulin high, C-peptide high, proinsulin high, β-hydroxybutyrate low, sulfonylurea screen negative); then localise (CT/MRI pancreas → EUS → molecular imaging → ASVS).[15]
• Treatment: surgery is the only curative method — enucleation is the most administered operation (56 per cent), with distal pancreatectomy (32 per cent) for deep lesions.[16] Pre-operative and unresectable-disease glycaemic control: diazoxide, somatostatin analogues, and everolimus; radiolabelled somatostatin analogue therapy (Lu-177 octreotate) and everolimus achieved normoglycaemia in refractory malignant cases.[17][18]
• Prognosis: high cure rate with surgery, but recurrence occurs in about 7 per cent after operation.[16]

Sulfonylurea-induced hypoglycaemia — the dangerous drug

The commonest cause of severe hypoglycaemia in older T2DM. In reported series glyburide (glibenclamide) and glipizide are the usual agents.[25] Hypoglycaemia can be sustained and profound and refractory to IV dextrose, particularly in children and the elderly; in adults, time to hypoglycaemia after overdose was 1-13 h and recurrence occurred in 22-50 per cent despite octreotide.[12] Treatment is octreotide plus only the dextrose that is needed, not escalating dextrose alone.[12][22]

Alcohol-induced hypoglycaemia

Alcohol suppresses hepatic gluconeogenesis, and hypoglycaemia in the malnourished drinker may have its clinical signs initially masked by drunkenness at presentation. Treat chronic alcohol misusers with a suspected poor diet with parenteral B vitamins at the outset, before or alongside dextrose, to prevent Wernicke encephalopathy. [27]

Adrenal crisis presenting as hypoglycaemia

In primary adrenal insufficiency (Addison's) cortisol deficiency impairs gluconeogenesis; secondary adrenal insufficiency is also a recognised cause. Keep the diagnostic and therapeutic threshold low in the acutely ill: treat empirically with parenteral hydrocortisone before confirmatory testing, and do not delay treatment for a corticotropin stimulation test — the 250 μg short corticotropin test is the gold standard once the patient is stable, and patients should be equipped with a glucocorticoid preparation for parenteral emergency use.[28]

Non-islet cell tumour hypoglycaemia (NICTH)

IGF-II-mediated (non-islet cell tumour) hypoglycaemia is caused by tumours — most often fibrous tumours (53 per cent of 233 reported patients), followed by tumours originating from the liver, haemangiopericytomas and mesotheliomas. Hypoglycaemia was the presenting feature in 42 per cent, with loss of consciousness (27 per cent) and confusion (21 per cent) the commonest reported features. Surgical removal is the most employed treatment (47 per cent); corticosteroids, octreotide, diazoxide, embolisation and radiotherapy have disparate success rates, with an overall recovery rate of 77 per cent — chronic liver disease predicts a poor outcome.[9]

Post-gastric-bypass hypoglycaemia

Occurs months to years after Roux-en-Y. Mechanism is exaggerated postprandial GLP-1 and incretin response driving endogenous hyperinsulinaemia (sometimes true beta-cell hyperplasia, historically called nesidioblastosis). Workup is a mixed-meal test. Treatment is small frequent low-glycaemic meals, acarbose, diazoxide, octreotide; rarely partial pancreatectomy. [1]

Autoimmune insulin syndrome (Hirata syndrome)

Insulin autoantibodies (often triggered by sulfhydryl drugs — methimazole, captopril — or by viral illness in HLA-DR4 individuals) bind postprandial insulin, then release it hours later, producing late postprandial hypoglycaemia. Diagnostic: high total insulin, low free insulin, positive insulin antibodies, low C-peptide at the time of release. Often self-limiting; low-carbohydrate diet, glucocorticoids, plasmapheresis for severe cases. [1]

Factitious / surreptitious hypoglycaemia

Suspect in healthcare workers, patients with diabetes in the family, or those with psychiatric history. The workup is identical to insulinoma; the discriminator is:

• Self-injected insulin → high insulin, LOW C-peptide.
• Sulfonylurea ingestion → high insulin, high C-peptide, POSITIVE sulfonylurea screen.
• A careful history, a search for injection marks, and review of the patient's access to insulin and oral hypoglycaemics are crucial. [1]

Neonatal and paediatric hypoglycaemia

• Neonate of a diabetic mother — fetal hyperinsulinaemia from maternal hyperglycaemia; transient hypoglycaemia within hours of birth.
• Premature / IUGR / SGA infants — limited glycogen and fat stores.
• Inborn errors — galactosaemia, hereditary fructose intolerance, glycogen storage disease types I and III, fatty-acid oxidation defects (MCAD), organic acidaemias.
• Idiopathic ketotic hypoglycaemia — the commonest cause after age 1 year; fasting hypoglycaemia with ketonuria; treats with avoidance of prolonged fasting and uncooked cornstarch at bedtime.
• Congenital hyperinsulinism — ABCC8/KCNJ11 mutations; severe persistent neonatal hypoglycaemia with suppressed ketones; diazoxide, glucagon infusion, near-total pancreatectomy if refractory.
• Beckwith-Wiedemann syndrome — macrosomia, macroglossia, omphalocele, hemihypertrophy, neonatal hypoglycaemia. [1]

How hypoglycaemic patients come to harm

Complications

• Acute: seizures, coma, arrhythmia (QT prolongation, torsades), cardiac arrest, falls and injury (especially in the elderly), aspiration.
• Cerebral oedema — particularly in children given large glucose boluses; use 10% not 50% in children.
• Permanent neurological injury — if coma is prolonged (over 30-60 min); cortical blindness, persistent vegetative state.
• Hypoglycaemia-associated autonomic failure (HAAF) and unawareness — recurrent hypoglycaemia shifts the threshold; reversible with 2-3 weeks of strict avoidance.
• Mortality — sudden death (the dead-in-bed syndrome, presumed arrhythmia — hypoglycaemia causes an acquired long QT syndrome); estimated at 4.7 to 27.3 per cent of all unexplained deaths in type 1 diabetes.[30][26]
• Vascular events — in the ADVANCE trial, severe hypoglycaemia was associated with major macrovascular events (HR 2.88), death from a cardiovascular cause (HR 2.68) and death from any cause (HR 2.69), though whether hypoglycaemia contributes to adverse outcomes or merely marks vulnerability is debated.[6]
• Dextrose extravasation injury — 50% dextrose causes severe tissue necrosis if extravasated; use 10-20% where possible.
• Wernicke encephalopathy — precipitated by IV dextrose in thiamine-deficient patients; always give thiamine first.
• Octreotide side-effects — abdominal cramps, steatorrhoea, gallstones, bradycardia.
• Diazoxide side-effects — fluid retention, hirsutism, hyperglycaemia, nausea, hyperuricaemia.

Classic pitfalls

• Not checking glucose in a 'drunk' or 'seizing' patient — the cardinal error; hypoglycaemia is rapidly fatal if missed.
• Treating with glucagon in sulfonylurea overdose — it stimulates insulin release and worsens rebound.
• Giving 50% dextrose — irritant, extravasation injury; 10-20% preferred.
• Forgetting thiamine in the alcoholic — precipitates Wernicke.
• Not drawing the critical sample during a non-diabetic episode — once glucose is given, insulin, C-peptide, β-hydroxybutyrate are uninterpretable.
• Stopping the supervised fast too early and concluding 'not insulinoma' — the fast is prolonged by design; the fasting insulin, C-peptide, proinsulin and β-hydroxybutyrate criteria are validated diagnostic criteria for hyperinsulinaemic hypoglycaemia.[8]
• Misdiagnosing NICTH as insulinoma — insulin and C-peptide are LOW in NICTH; missing the tumour delays potentially life-saving resection.
• Assuming an unconscious diabetic is hyperglycaemic — they are more often hypoglycaemic; check the glucose.
• Not relaxing glucose targets after a severe episode — failure to reverse HAAF guarantees recurrence.
• Letting the patient drive home after recovery — DVLA prohibits driving for at least 45 min after a moderate episode and for some time after any severe episode.

Prognosis, disposition, and the unaware patient

Mild hypoglycaemia in a well patient, corrected by oral glucose, with a clear precipitant, may be managed with education and review — unintentional supratherapeutic ingestions can be managed outside hospital only if the patient stays asymptomatic and normoglycaemic. [13][19]

Severe hypoglycaemia mandates admission — for cause investigation (especially in non-diabetics), for observation after sulfonylurea or long-acting insulin overdose (24-48 h), and for regimen adjustment. The prognostic determinants are: [1]

• Underlying cause — reversible (skipped meal) versus persistent (insulinoma, NICTH).
• Duration and depth of hypoglycaemia — prolonged coma carries a risk of permanent neurological injury.
• HAAF/unawareness — predicts recurrence; relaxation of targets and CGM are mandatory.
• Comorbidity — renal, hepatic, cardiac, cognitive impairment all worsen prognosis.
• Adherence to follow-up — clinic review within 1-2 weeks; structured diabetes education; consider Diabetes Technology service. [1]

After recovery, the disposition decision:[2]

• Discharge in 4-6 hours if: episode was mild, fully reversed, the cause is clear and reversible (e.g. missed meal), the patient is neurologically intact, social situation is safe, no sulfonylurea/long-acting insulin involved.
• Admit if: severe episode, ongoing risk (sulfonylurea or long-acting insulin), recurrent, no clear cause, non-diabetic presentation, cognitive impairment, social isolation, or DVLA-relevant circumstance. [1]

Special Populations

Pregnancy

• Tighter glucose targets increase hypoglycaemia risk in T1DM and T2DM in pregnancy (especially first trimester and peripartum).
• Severe hypoglycaemia in pregnancy is common in T1DM — educate partners in IM glucagon; CGM mandatory.
• Gestational diabetes is rarely treated with insulin in doses high enough to cause severe hypoglycaemia.
• During labour, maintain glucose with a sliding-scale dextrose-insulin infusion; check glucose hourly.
• Intrapartum glucagon crosses the placenta but is preferred over prolonged hypoglycaemia. [1]

The elderly

• Atypical presentation (confusion, falls, focal signs mimicking stroke); always check glucose.
• Higher risk because of renal impairment, polypharmacy, cognitive impairment, irregular meals — sulfonylurea poisoning produces sustained and profound hypoglycaemia particularly in the elderly.[12]
• Practise hypoglycaemia risk-factor reduction: address the issue, apply the principles of intensive glycemic therapy with flexible and individualised regimens, and consider both conventional risk factors and those indicative of compromised counterregulation.
• Hypoglycaemia unawareness, a history of severe hypoglycaemia, endogenous insulin deficiency and aggressive glycemic therapy per se mark the high-risk patient. [10]

Children

• Idiopathic ketotic hypoglycaemia — commonest after age 1 year; treat with cornstarch and avoid prolonged fasting.
• Congenital hyperinsulinism — diazoxide, glucagon, surgery.
• Inborn errors — dietary management with metabolic team.
• Children with T1DM — HAAF develops rapidly; CGM and structured education of the family. [1]

Renal impairment

• Reduced clearance of insulin and sulfonylureas; gluconeogenesis impaired.
• Avoid glibenclamide (eGFR under 30); choose gliclazide, glipizide with caution; insulin doses usually reduced.
• Pre-dialysis patients are at particular risk of nocturnal hypoglycaemia. [1]

Driving

• DVLA Group 1 (car/motorcycle): no more than one severe episode in 12 months; no severe episode while driving; impaired awareness of hypoglycaemia requires notification and likely licence suspension until resolved.
• DVLA Group 2 (lorry/bus): must have no severe hypoglycaemia in the past 12 months and intact awareness; if insulin-treated, must demonstrate blood glucose monitoring at least twice daily and at relevant times.
• Patients are advised not to drive for at least 45 minutes after recovery from a moderate hypoglycaemic episode (long enough for cognitive recovery). [1]

Evidence, Guidelines & Regional Differences

Landmark trials

• ACCORD (2008, NEJM) — randomised intensive glucose lowering (HbA1c target under 6.0 per cent) versus standard therapy (7.0 to 7.9 per cent) in 10,251 high-risk patients with T2DM; the intensive arm was stopped early after a mean of 3.5 years for higher all-cause mortality (257 vs 203 deaths; hazard ratio 1.22), and hypoglycaemia requiring assistance was significantly more frequent.[29]
• ADVANCE (NEJM 2010) — among 11,140 patients with T2DM, severe hypoglycaemia was independently associated with major macrovascular events (HR 2.88), cardiovascular death (HR 2.68) and all-cause death (HR 2.69); the direction of causality is debated but the association is robust.[6]
• ACCORD follow-up (NEJM 2011) — intensive therapy reduced nonfatal myocardial infarctions but increased 5-year mortality; such a strategy cannot be recommended for high-risk patients with advanced T2DM.[7]

The "glucose paradox"

Tight glycaemic control prevents long-term complications but causes short-term hypoglycaemic harm — the glucose paradox. The lesson of ACCORD and ADVANCE is that glucose targets must be individualised, with more lenient targets for those at risk of hypoglycaemia — intensive targeting of near-normal HbA1c in high-risk T2DM increased mortality.[7][29]

Guideline deltas

• Endocrine Society (2009) — the canonical evaluation-and-management guideline for adult hypoglycaemic disorders: Whipple's triad as the gate, clinical-clue-led evaluation (drugs, critical illness, hormone deficiency, non-islet cell tumour), the critical-sample biochemistry during an episode, and hypoglycaemia risk-factor reduction in diabetes.[1]
• ADA / Endocrine Society Workgroup (2013) — reconfirmed the previous definitions of hypoglycaemia in diabetes, set out strategies to prevent hypoglycaemia, and provided tools for patients to report hypoglycaemia at every visit.[2]
• NICE NG28 (UK) and JBDS-IP (UK) — UK guidance mirrors the treat-early, treat-then-investigate approach; treat any symptomatic documented low glucose promptly and audit the regimen afterwards.
• Indian (RSSDI, ICMR) — Indian guidance mirrors ADA principles with regional drug-availability adjustments.

Controversies

• The threshold for clinical hypoglycaemia — counterregulatory hormones activate at about 3.6 to 3.8 mmol/L (65 to 68 mg/dL), autonomic symptoms at about 3.2 mmol/L (58 mg/dL), and cognitive dysfunction below 3 mmol/L; antecedent hypoglycaemia shifts all of these thresholds down (HAAF).[21][11][10]
• Self-monitoring vs CGM — prevention rests on education, individualised regimens and awareness of risk factors; CGM is an adjunct in hypoglycaemia-prone disease.[10][17]
• Glucagon formulations — a needle-free intranasal glucagon performed as well as reconstituted injectable glucagon in a randomised crossover trial and avoids the reconstitution step prone to error or omission.[20]

Exam Pearls

• Whipple's triad — symptoms + documented low glucose + relief with glucose. Without all three, do not investigate for organic causes.
• Thresholds: counterregulatory activation about 3.6 to 3.8 mmol/L; autonomic symptoms about 3.2 mmol/L (58 mg/dL); cognitive dysfunction below 3.0; severe = needing another's help.[21][11][29]
• The 15-15 rule — 15-20 g oral glucose or sucrose, recheck after 10-15 min, repeat if still low.[19]
• Severe hypoglycaemia — IV 10% dextrose OR IM glucagon 1 mg.[19]
• Sulfonylurea overdose — dextrose itself drives further insulin release; the specific therapy is octreotide 50 mcg SC/IV with further 50 mcg doses 6-hourly, and dextrose only as needed.[12][14][22]
• Always give parenteral B vitamins (thiamine) at the outset in chronic alcohol misuse or malnutrition, before or with dextrose (Wernicke prevention).[27]
• The 5 questions to ask in any unconscious/seizing patient — glucose, oxygen, opioids, intracranial event, sepsis.
• Insulinoma — Whipple's triad + weight gain; insulin HIGH, C-peptide HIGH, proinsulin HIGH, β-hydroxybutyrate LOW, sulfonylurea screen NEGATIVE.[15]
• Exogenous insulin abuse — insulin HIGH, C-peptide LOW, proinsulin LOW.
• Sulfonylurea ingestion (factitious) — insulin HIGH, C-peptide HIGH, sulfonylurea screen POSITIVE.
• Non-islet cell tumour hypoglycaemia (NICTH) — insulin LOW, C-peptide LOW; big tumour (fibrous tumours commonest, then liver tumours).
• HAAF — recurrent hypoglycaemia shifts the autonomic and glucagon thresholds to LOWER glucose; reversible with 2-3 weeks strict avoidance; relax HbA1c target.
• The "dead in bed" syndrome — sudden death in the early morning in an undisturbed bed in young T1DM, typically after recurrent severe hypoglycaemia; 4.7 to 27.3 per cent of unexplained T1DM deaths in reported series.[30]
• ACCORD stopped early for excess mortality in the intensive glucose-lowering arm.[29]
• ADVANCE: severe hypoglycaemia nearly tripled major macrovascular events (HR 2.88) and more than doubled cardiovascular death (HR 2.68).[6]
• β-hydroxybutyrate is suppressed when endogenous insulin is high — a core component of the Endocrine Society critical sample.[1]
• Octreotide is the antidote to sulfonylurea-induced hypoglycaemia (suppresses insulin secretion).[25]
• Pregnancy + T1DM — high hypoglycaemia risk in first trimester; CGM mandatory.
• DVLA — impaired awareness of hypoglycaemia is notifiable; one severe episode in 12 months (Group 1) or any severe episode (Group 2) is reportable.
• Acarbose patients — use pure glucose (dextrose), not sucrose (sucrose digestion blocked by acarbose).

Ward-round test — three stems, thirty seconds each

Stem 1 — the man from the top of the topic (answer)

A 72-year-old with type 2 diabetes on glibenclamide is found unconscious, clammy, capillary glucose 1.8 mmol/L. What do you give, and why is one bolus not enough? Model: Severe hypoglycaemia from a sulfonylurea. Give IV 10% dextrose (or IM glucagon 1 mg if there is no IV access) to correct the moment.[19] One bolus is not enough because sulfonylurea-driven insulin release keeps recurring: give octreotide 50 mcg SC or IV, followed by three further 50 mcg doses every 6 h, use dextrose sparingly (it stimulates more insulin release), and observe for 12 h after dextrose and octreotide are discontinued — recurrence occurred in 22-50 per cent in reported adult series.[12][13][22] Audit the regimen and the renal function once he is stable.

Stem 2 — the non-diabetic who keeps collapsing (answer)

A 40-year-old non-diabetic has recurrent early-morning confusion relieved by food, with a documented glucose of 2.1 mmol/L during an attack. What gate must she pass before any investigation, and which critical sample splits insulinoma from injected insulin? Model: She must satisfy Whipple's triad — symptoms, a concomitant low glucose, and relief with glucose — before any invasive work-up is justified. During the next episode draw the critical sample: glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and a sulfonylurea screen, with insulin antibodies if endogenous hyperinsulinism is suspected — the Endocrine Society panel. Once clinical clues (drugs, critical illness, hormone deficiency, non-islet cell tumour) are excluded, the guideline's differential narrows to accidental, surreptitious or malicious hypoglycaemia versus endogenous hyperinsulinism, and this panel resolves it; the fasting insulin, C-peptide, proinsulin and beta-hydroxybutyrate criteria are validated for hyperinsulinaemic hypoglycaemia (sensitivity over 90 per cent).[1][8]

Stem 3 — the stroke that was not a stroke (answer)

A 65-year-old is brought in with right-sided weakness and slurred speech; the team has activated the stroke pathway. Name the single bedside test that must not be omitted, and why. Model: A finger-prick glucose — now. Hypoglycaemia is a classic stroke mimic (focal neuroglycopenia, even hemiparesis), and it is excluded at the bedside in moments. If the glucose is low, give IV dextrose and the deficit often resolves within minutes. The rule is absolute: check glucose in every collapse, seizure, confusion, or focal neurological presentation before committing to a stroke or neurology pathway — a missed hypoglycaemia is a preventable harm.[1]

References

1. [1]Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab, 2009.PMID 19088155
2. [2]Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig T, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society Diabetes Care, 2013.PMID 23589542
3. [5]Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes Endocr Pract, 2008.PMID 18996798
4. [6]Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death N Engl J Med, 2010.PMID 20925543
5. [7]Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med, 2011.PMID 21366473
6. [8]Placzkowski KA, Vella A, Thompson GB, Grant CS, Reading CC, Charboneau JW, Andrews JC, Lloyd RV, Service FJ. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007 J Clin Endocrinol Metab, 2009.PMID 19141587
7. [9]Ata F, Choudry H, Khan AA, et al. A systematic review of literature on Insulin-like growth factor-2-mediated hypoglycaemia in non-islet cell tumours Endocrinol Diabetes Metab, 2024.PMID 38411039
8. [10]Cryer PE. Hypoglycemia in diabetes Diabetes Care, 2003.PMID 12766131
9. [11]Frier BM. Hypoglycaemia and cognitive function in diabetes Int J Clin Pract Suppl, 2001.PMID 11594296
10. [12]Glatstein M, Scolnik D, Bentur Y. Octreotide for the treatment of sulfonylurea poisoning Clin Toxicol (Phila), 2012.PMID 23046209
11. [13]Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose Br J Clin Pharmacol, 2016.PMID 26551662
12. [14]Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses J Clin Endocrinol Metab, 1993.PMID 8445035
13. [15]Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma World J Gastroenterol, 2013.PMID 23430217
14. [16]Mehrabi A, Fischer L, Hafezi M, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma Pancreas, 2014.PMID 24921202
15. [17]Matej A, Bujwid H, Wroński J. Glycemic control in patients with insulinoma Hormones (Athens), 2016.PMID 28222404
16. [18]Ong GSY, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma Eur J Endocrinol, 2010.PMID 20164213
17. [19]Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review Diabet Med, 2017.PMID 28477413
18. [20]Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study Diabetes Care, 2016.PMID 26681725
19. [21]Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction Am J Physiol, 1991.PMID 1987794
20. [22]Baumgartner K, Devgun J. Toxicology of Medications for Diabetes Mellitus Crit Care Clin, 2021.PMID 34053707
21. [23]Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies Expert Rev Anticancer Ther, 2018.PMID 29973077
22. [24]Chandran S, Pravin R, Chua MC, et al. Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia Arch Dis Child Fetal Neonatal Ed, 2022.PMID 34544689
23. [25]McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia Ann Emerg Med, 2000.PMID 10918104
24. [26]Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia Diabetes, 2003.PMID 12765959
25. [27]Thomson AD, Cook CC, Touquet R, Henry JA. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department Alcohol Alcohol, 2002.PMID 12414541
26. [28]Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab, 2016.PMID 26760044
27. [29]Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med, 2008.PMID 18539917
28. [30]O'Reilly M, O'Sullivan EP, Davenport C, Smith D. Dead in bed: a tragic complication of type 1 diabetes mellitus Ir J Med Sci, 2010.PMID 20658206